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As an agricultural and food company, Cargill is and remains a strong supporter of ag-
ricultural biotechnology. Cargill believes that this technology has an important role in 
nourishing the people of the world. But agricultural biotechnology’s benefits are limited 
if these innovations cannot be effectively integrated into the global food system. Interna-
tional solutions are needed to deal with the current challenges of asynchronous approvals, 
where a technology is approved in an exporting country but not in an importing one. 
Compounding the asynchronous issue are policies in some countries with zero tolerance 
for the presence of any materials derived from biotechnology. The best solution lies with 
governments finding ways to synchronize approvals and moving the requirement for 
approved genetically modified traits off of zero tolerance.
Over the last ten years there have been significant changes in agricultural biotechnologies, 
in both business opportunities and risks. To understand the complexity of the market-
place, a broad overview on the US grain-handling system is in order. Firstly and most 
importantly, price and quality are the key drivers for both our domestic and international 
customers. The US bulk handling system is one of the most highly efficient grain-handling 
infrastructures in the world. Over the last 150 years, it has evolved to become world class 
in its ability to move large quantities of agricultural products from areas of surplus to 
areas of need. It generates tremendous value from farm to fork.
The result is a system based on grain standards that include reasonable tolerances 
and thresholds for commingling. This provides market access to fungible, high-quality 
agricultural products at low costs. It is this high-volume, efficient supply chain that has 
enabled it to be a fierce competitor in global agriculture and enabled the United States to 
remain a key agricultural supplier to the world. Sameness or interchangeability is a critical 
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component in commodity-handling systems and provides the flexibility to move grains 
and oilseeds efficiently. Over the last 100 years, essentially all countries have developed 
their bulk handling systems to take advantage of such fungibility.
Farmers have widely embraced growing a generic product, with clear specifications. 
This provides flexibility in where and when they can deliver their product and enables 
them to maximize profits through competitive price discovery. Specialty grains can deliver 
premiums to farmers but also trade off flexibility in where they can be raised and when 
they can be sold.
For those who originate and handle grain, fungibility has been a key attribute to en-
able efficient supply chains. Being able to substitute grain volumes ensures that there is 
a source of grains when there are crop failures or disease outbreaks in specific regions or 
countries. Swapping consignments of grain enables companies to arbitrage and find the 
lowest cost logistics when supply and demand ebb and flow, thus maximizing efficiencies 
and minimizing food miles.
Governments have developed grain standards and industry specifications to enable a com-
modity grain system to work. In response to governments and competitiveness on price, 
the private sector has responded with deliberate investments in large, high-throughput 
storage infrastructure and moving products with 100-car-unit trains, groups of barges, 
and large ocean-going vessels.  
For both domestic and international customers, these generic grains have provided ac-
cess to a safe, low-cost, and predictable food supply chain. For customers, it enables the 
bidding system for price discovery and access to the lowest-cost grains. It allows customers 
to source multiple origins and regions to ensure predictable supply and manage demand 
and price. It provides consistency in quality and safety, and predictability for running 
their manufacturing businesses. 
But the bulk handling system, as it has evolved, is not designed for significant market 
segmentation or deconstruction into a series of parallel grain-channeling programs. This 
market segmentation quickly erodes price and competitiveness. It undermines fungibility 
and flexibility and all the benefits a commodity supply chain creates. It especially cannot 
operate effectively with zero-tolerance requirements.
For those involved in the agricultural industry, there should be little debate about the 
importance of exports to agricultural producers in helping maintain and grow demand 
for agricultural products. American Farm Bureau statistics tell an important story: one 
in three US farm acres is planted for export; 31 percent of US gross farm income comes 
directly from exports. There are large and important markets to serve, and exports are key 
to improving overall food security. Agricultural biotechnology’s benefits to global food 
security are limited if they cannot be effectively integrated into the global food system.
Here is a simple illustration of the steps in a typical supply chain for a raw agricultural 
commodity: 
•	 Crops	are	transported	from	farms	to	grain	elevators.	Grain	elevators	are	most	
often designed for scale to help manage costs. For corn and soybeans, elevators 
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often have limited segregation capabilities, so they mainly accept generic  
commodities, such as yellow soybeans or number 2 yellow corn. 
•	 A	typical	elevator	accumulates	grain	from	hundreds	of	different	farms.	Once	
elevated to the bin, the grain from a farm becomes part of a larger consignment, 
and there is no way to retrieve only that specific parcel again. Accepting some-
thing that is not allowed or has a negative attribute becomes very expensive very 
quickly, as it implicates larger consignments of grain.
•	 Bulk	grain	is	further	aggregated	when	sent	for	processing,	either	domestically	or	
abroad. Most of the infrastructure is common regardless of whether the grain is 
processed domestically or transported to an export market. 
•	 Once	aggregated	at	export,	a	shipment	of	grain	may	contain	product	harvested	
from thousands of different farms. As such, the needs of the domestic and export 
markets must coexist.
Next, let us look at how GM crops have been integrated into agricultural supply chains 
over the last 15 years. The introduction of GM crops has added a new layer of complex-
ity to the system. It has created a need for additional regulation, and today compliance 
requirements can differ by market. It has also created demand for non-GM products, 
which requires segregated supply chains for handling crops produced with and without 
biotechnology. Over this period of time we have learned a number of valuable lessons.
The integration of GM products into agricultural supply chains requires national 
frameworks to support the assessment and management of any risks associated with the 
use of biotechnologies. Product safety always comes first, and we believe governments 
can play an important role. While some see regulation as a barrier to innovation, national 
frameworks enable market participants to integrate new technologies into agri-food sup-
ply chains with confidence. Safety reviews by government authorities and independent 
scientific bodies provide assurances to industry and consumers. It is essential to know that 
a product is considered safe and is approved before it arrives at our facility.
We consider products to be safe if they have cleared governmental reviews consistent 
with Codex international risk assessment guidelines. Unfortunately, the existence of an 
international standard for safety assessment (Codex) has not prevented this problem. 
While national frameworks are essential, the lack of harmonization poses significant chal-
lenges. While current difficulties are not what was envisioned a decade ago, individual 
countries and more specifically key trading partners have not effectively coordinated 
regulatory approvals for new traits. National differences in both the timing and process 
for approving new traits can lead to regulatory compliance issues that must be managed. 
As such, agricultural commodities without key export market approvals are not fungible 
commodities and just because they are safe, does not mean they are equal and allowed to 
flow freely in international commerce. 
Zero tolerance for unapproved traits has become a common regulatory requirement for 
commodities, yet totally unattainable after commercialization. As such, the commercial-
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ization of new GM traits before export market approval is a key issue to be addressed by 
industry and governments based on the risks asynchrony creates for producers and the 
US agricultural industry. Without a solution, asynchronous approvals can severely hamper 
the movement of commodities from areas of surplus to areas of need. It undermines food 
security goals. At no time has this been more acute than the present.
An increasing focus on testing and enforcement adds pressure to asynchronous ap-
provals. High-profile field escapes and awareness of asynchronous approvals reinforce 
government interest in testing and compliance activities. Driven by the need to assure 
regulatory compliance, GMO detection capabilities have advanced rapidly in recent years. 
Governments have invested heavily in efforts to improve methodologies, sensitivity, and 
speed. Testing technologies are now readily accessible and cost effective, and barriers to 
entry are low.
There are different views on this issue, depending on location in the value chain. From 
the technology perspective, there is a drive to commercialize, to start recouping the invest-
ment and to enjoy as much of a patent’s life as possible. Technology companies spend 
significant amounts of money to both develop and obtain approvals for their traits. There 
is also a demand from farmers who want access to innovations that promise improved 
performance on their farms, to help them improve agronomics and yield.  
It is a bit more complicated for the producer. The producer looks to maximize value 
creation on his farm, and this is a combination of yield and the market price for his 
grains. As such, producers are looking for both what can bring them the best yields and 
the marketability of those products. Individual grower decisions to produce GM products 
that lack export market approvals can both create marketability issues for that individual 
producer and, if not managed effectively by the technology company, dramatically increase 
cost and risk to the entire supply chain.  
Most of the costs and risks that occur when unapproved traits are introduced into 
the supply chain are realized more broadly across the US producer base, grain handlers, 
and exporters. There are key examples that illustrate this to be the case. Ultimately, these 
additional costs and risks have the potential to reduce US competitiveness, by restricting 
access to markets where these products are not yet approved, by challenging the reliability 
of the origin as a key supplier, and by making US products less competitive on price.  
Current market conditions, including the size of the export market, can change the 
calculus of this decision.  The best outcome is for US agriculture to have both innovation 
and market access. As asynchronous approval barriers have emerged, industry approaches 
to address them have varied over time. Dialogue between the grain and export industry 
and government is essential and remains a key activity. It is clear, however, that there will 
be no quick fix to the patchwork of national approval systems. For integration of GM 
crops into global food systems, solving asynchronous approvals remains elusive.
Sensing long timelines, there is a growing impatience amongst some technology companies, 
who want to commercialize now. Over the last decade they have been exploring new ways 
to bring their products to market and are pushing the limits. The starting point a decade 
ago was “no commercialization ahead of key market approvals.” This expectation was set 
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early by the soybean growers in the US, recognizing that they needed both innovation 
and market access. There is strength in being the preferred and predictable supplier to the 
world’s markets. With a large export program it is easy to put the customer first.  This has 
paid off for soy producers, who have been able to near double their export demand to over 
$20 billion over the last decade, while at the same time using agricultural biotechnology 
to improve both agronomics and sustainability.
For the corn industry, producers chose to rely much less heavily on exports, and dif-
ferent approaches to asynchronous approvals were used. One approach to asynchronous 
approvals was to broadly commercialize the GM event in the absence of the key market 
approval to apply political pressure in the destination market and force an approval 
before harvest. That happened in 2007.  This broad commercialization decision drew 
significant attention from exporters in 2007, when the US corn market—the number 
one corn export market in the world—was put at risk. The industry hoped to never see 
that approach again.
One of the positive outcomes from this crisis in 2007 was the recognition and rein-
forcement across the value chain that US agricultural systems are interdependent. What 
followed were important cross-sectoral discussions around the need for a responsible 
commercialization model. This catalyzed the development of the Biotechnology Industry 
Organization (BIO) product launch stewardship policy and subsequently a similar global 
commitment through CropLife International (CLI). Both stewardship policies promoted 
“pre-commercialization” through tightly controlled closed-loop programs. In this case, 
technology owners hope to enable both innovation and market access by channeling the 
product away from the not-yet-approved markets.
Over time and based on the realities of the grain-handling system, it has been very dif-
ficult for biotechnology providers to demonstrate that they can completely segregate these 
products. There have been some valuable lessons over the last decade about the limits 
of closed-loop grain-channeling programs: if not managed effectively, they tend to leak. 
When they are poorly managed and leak, exporters have generally been expected to keep 
these unapproved events away from the export markets. Managing the presence of an 
export-unapproved GMO in the commodity supply can have a significant operational 
and financial impact on those outside of the closed-loop supply chain.
Some of the most important lessons have been:
•	 Outcomes	are	more	important	than	process.	Early	attempts	to	channel	corn	 
away from the EU market demonstrated that it is not the plan on paper, but  
the execution of the plan that counts. Tying outcomes to responsibility is an 
important feedback loop. 
•	 When	containment	systems	fail,	a	little	goes	a	long	way.	Based	on	the	level	of	
commingling that happens in the grain supply, a very small amount of produc-
tion can have an impact on a very large amount of grain. With less than 1/10th of 
1 percent of the corn supply planted to an unapproved trait, at one point 60% of 
the barges containing corn by-products feed, intended for EU customers, tested 
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positive and therefore, unacceptable for export. In the end, the prevalence and 
risk of the trait made it too expensive and risky to continue the trade flow, and 
that opportunity to export evaporated.
•	 Most	importantly,	zero	is	a	very	small	number.	For	a	zero-tolerance	requirement,	
we have learned through experience that testing is not a robust risk management 
solution. Vessels may test negative at origin and test positive at destination; these 
have been powerful and expensive lessons. 
With a recognition of the reality of agricultural systems and a zero-tolerance threshold, 
grain channeling is not a substitute for a key export market approval. Grain channeling 
has a role to play if executed with rigor, but this also adds cost and risk to the broader 
agriculture supply chain. These costs and risks need to be accounted for as part of closed-
loop commercialization decisions. So given the realities of commodity supply chains, 
timing differences in government approvals, and varied commercial interests, where do 
we go from here? 
There have been a number of conversations going on about how to sensibly address 
this issue in a manner that supports and encourages both innovation and market access. 
One of those has been a healthy discussion across the full value chain to look for consen-
sus on what responsible commercialization standards would look like for the industry.
That discussion was built on recognition that commercialization ahead of key export 
market approval creates both costs and risks. Recognizing this alone has been important, 
so the discussion can begin about who should cover these additional costs and risks. 
Exporters and handlers will not accept all of the risk and costs that unapproved GM 
event commercialization brings to US agriculture. There is a growing recognition that 
when technology companies decide to commercialize early, grain handlers and exporters 
expect those who earn the value to also own the risk. At a minimum, the risk and reward 
should be shared. 
The recent National Grain and Feed Association economic case study developed in April 
2014 provides sense for such impacts. Based on conservative NGFA estimates, corn created 
approximately $80 million in economic value that accrued to the technology owner, seed 
sellers, and selected producers who grew it on 4 percent of US corn acres. But the resulting 
market disruption is estimated at $1.0–2.9 billion dollars in damages to all producers, 
handlers, and exporters. In this case study, it is clear that US agriculture lost significantly 
more than it gained from this aggressive commercialization decision. 
The best solution lies with governments finding ways to synchronize approvals and 
moving the requirement for safety-approved GM traits off of zero tolerance. Governments 
should address these difficult challenges and find solutions quickly. This patchwork has 
turned out to be difficult to manage and is limiting biotechnology’s integration into the 
global food system. Surely there are better ways to align and recognize the commonalities in 
approaches and assessments. It will take leadership and creativity to make significant gains. 
Unresolved, asynchronous approvals slow innovation, erode the value of technology, 
and hinder the role of agricultural biotechnology in helping to address our food security 
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goals. In the near term there is an opportunity to address zero-tolerance policies for GM 
events that have been fully approved for food and feed use but not yet approved in a 
given importing country through the Global LLP Initiative. There is also some growing 
traction with governments to move off of zero tolerance. It is an opportunity to mutually 
recognize existing safety assessments, respect existing biosafety laws and, in a very practical 
way, address zero tolerance in the interim while full approval processes are completed.
There is a role for the US government to show leadership here by demonstrating a proac-
tive and clear low-level-presence policy for the US. Many countries look to the US for 
guidance, and we need to walk the talk. Until these international challenges are resolved, 
the US value chain should be encouraged to continue to do the hard work in setting 
expectations around responsible commercialization. The stakes are high for everyone, and 
for real progress to emerge, technology companies will need to ensure they are standing 
together so that responsible commercialization standards are viewed as essentially manda-
tory. This will take strong commitment from them. 
Over the 15 years since the commercialization of GM crops, we all have learned how 
interdependent agricultural supply chains are and that the best solutions will emerge when 
we are all pulling in the same direction. Even with the best efforts of industry, we will not 
resolve the issue of asynchronous approvals alone. Some of the key policy decisions for 
addressing asynchronous approvals fall to government, and those national government 
policy decisions have the potential to either improve or disrupt the implementation of 
agricultural biotechnology. There is no question that the quality of their policy decisions 
influences price, supply chain access, and food security impacts. The full value of the 
technology can be recognized with all stakeholders working together.
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